Activated vitamin D3 formulations can be safely used as concomitant medication for prevention of denosumab‐induced hypocalcemia in women with postmenopausal osteoporosis-Reference-Cited by-同舟云学术

Activated vitamin D3 formulations can be safely used as concomitant medication for prevention of denosumab‐induced hypocalcemia in women with postmenopausal osteoporosis

Published:2019-01-07 Issue:4 Volume:45 Page:908-914
ISSN:1341-8076
Container-title:Journal of Obstetrics and Gynaecology Research
language:en
Short-container-title:J. Obstet. Gynaecol. Res.

Author:

Saito Shin¹,Sugo Yoshinobu¹,Tsuburai Taku²,Kurasawa Kentaro¹,Nakamura Tomomi¹,Yoshikata Hiromi²,Miyagi Etsuko¹,Sakakibara Hideya²

Affiliation:

1. Department of Obstetrics and GynecologyYokohama City University Medical Center Yokohama Japan

2. Department of GynecologyYokohama City University Medical Center Yokohama Japan

Publisher

Wiley

Subject

Obstetrics and Gynaecology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jog.13913

Reference20 articles.

1. Signaling Axis in Osteoclast Biology and Therapeutic Targeting in the RANKL/RANK/OPG System

2. Vitamin D and calcium are required at the time of denosumab administration during osteoporosis treatment

3. Comparison of the effects of denosumab between a native vitamin D combination and an active vitamin D combination in patients with postmenopausal osteoporosis

4. Comparison of the effects of denosumab with either active vitamin D or native vitamin D on bone mineral density and bone turnover markers in postmenopausal osteoporosis

5. Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The effects of alfacalcidol combined with calcitonin in the treatment of osteoporosis and its influence on levels of inflammation;American Journal of Translational Research;2024

2. The preparation of pre-alphacalcidol by high performance liquid chromatography;Materials Express;2023-11-01

3. Denosumab in chronic kidney disease: a narrative review of treatment efficacy and safety;Archives of Osteoporosis;2021-07-28